WASHINGTON — The head of the Food and Drug Administration is facing heavy fire from the pro-life community amid reports that he slow-walked a review of abortion drugs promised by Health and Human Services Director Robert F. Kennedy Jr. The backlash followed a Bloomberg report on Monday stating that the FDA had delayed its review